Standard BioTools (LAB) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Standard BioTools

NasdaqGS•Healthcare•Medical Devices

$0.69-0.04(-0.05%)After hours

Market Cap

$269.71M

P/E

3.2x

P/S

4.2x

P/B

0.5x

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

How this company scores

AverageMetricSide Score: 49/100

Strongest: Balance Sheet & Red Flags (21/25); weakest: Cash & Earnings Quality (6/25).

Profitability14/25

Growth8/25

Balance Sheet & Red Flags21/25

Cash & Earnings Quality6/25

Strengths

High ROERising earningsLow leverageProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 3.2x5y range 3.2x – 4.6x

P/S · 4.2x5y range 1.1x – 5.6x

Currently above its 20-quarter median.

P/B · 0.5x5y range 0.5x – 6.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $269.71M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $64.02M
Q. Revenue: $20.10M
TTM EBITDA: $-83.97M
TTM Op. Income: $-89.47M
Q. Op. Income: $-25.39M
TTM Net Income: $84.91M
Q. Net Income: $-26.76M
EPS: $-0.07
Shares Out.: $390.88M

$64.02M in TTM revenue declined 58.5% YoY, reaching $20.10M last quarter. TTM EBITDA of $-83.97M and TTM operating income of $-89.47M show growth is flowing through to the bottom line. TTM net income of $84.91M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has fallen for 6 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 52.4%
EBITDA Margin: -120.0%
Op. Margin: -126.3%
Net Margin: -133.1%

Op. margin of -126.3% is down 8.2% YoY — costs are rising relative to revenue. Net margin at -133.1% and gross margin of 52.4% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 7% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 3.2x
P/S Ratio: 4.2x
P/B Ratio: 0.5x

At 3.2x P/E, the stock trades below typical market levels. P/S of 4.2x and P/B of 0.5x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 0% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $627.22M
Cash: $270.03M
Long-Term Debt: $299,000
Book Value: $539.97M
D/E Ratio: 0.0
Debt/EBITDA: N/A

With $627.22M in assets and $299,000 in long-term debt, D/E is 0.0and book value is $539.97M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 21% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-10.31M
TTM Free Cash Flow: $-82.58M
FCF Margin: -129.0%
FCF / Net Income: -1.0

TTM FCF of $-82.58M on $-10.31M in operating cash flow. The FCF / Net Income ratio of -1.0x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is up 22% — an improving trend.